Cancer News

More treatment options for non-small cell lung cancer

The drug Alectinib (Alecensa) received approval by the FDA for the treatment of patients with advanced, metastatic, ALK-positive non-small cell lung cancer.

U.S. approval of an antidote for chemotherapy overdosing

U.S. regulators approved the drug uridine triacetate (Vistogard) for the treatment of overdoses of the chemotherapy drugs fluorouracil and capecitabine.

Breast cancer survival linked to delayed treatment

Delaying treatment and chemotherapy influences the survival rates of breast cancer patients, two large U.S. studies suggest.

Comparing two treatments for common type of breast cancer

Postmenopausal women with ductal carcinoma in-situ treated with anastrozole saw no difference in outcome compared to treatment with tamoxifen.

Is breast-conserving therapy better for breast cancer patients?

Early-stage breast cancer patients who received breast-conserving surgery plus radiation therapy instead of mastectomy lived longer, scientists report.

Sharing symptoms online boosts cancer patients’ survival

Cancer patients who shared their symptoms online improved their quality of life and stayed on treatment longer, a new research points out.

Increased survival for patients with triple-negative breast cancer

Patients with triple-negative breast cancer who had no residual invasive cancer detected after pre-surgery chemotherapy lived longer, scientists discovered.

Adjuvant chemotherapy: not effective for all breast cancer patients

Premenopausal women whose invasive breast cancers were of the luminal A subtype did not benefit from a treatment with adjuvant chemotherapy.

Improved outcomes for breast cancer patients with capecitabine

Breast cancer patients with residual disease after pre-surgery chemotherapy lived longer after being treated with the chemotherapy agent capecitabine.

Combing palbociclib with paclitaxel against advanced breast cancer

The combination of the palbociclib with paclitaxel (Taxol) induced positive patient outcomes when administered to estrogen-receptor positive breast cancer patients.

Denosumab reduces breast cancer relapse rate

The monoclonal antibody (denosumab) given as adjuvant therapy with aromatase inhibitors reduced disease relapse rate in breast cancer patients.

Anxious about getting a genetic cancer screening?

Counseling before and after a genetic cancer screening helped BRCA 1/2-negative patients make informed decisions and deal with anxiety, a new research reveals.

Linking breast cancer treatment and leukemia

Breast cancer survivors at risk of developing leukemia due to chemotherapy and/or radiation share certain characteristics, a new analysis shows.

Experimental drug improves survival in high-risk AML patients

The drug Midostaurin added to standard chemotherapy improved survival in patients with acute myeloid leukemia carrying mutations in the FLT-3 gene, scientists report.

Blinatumomab brings hope to acute lymphoblastic leukemia patients

Blinatumomab proved to be efficient and safe for the treatment of adult patients with acute lymphoblastic leukemia.

Multiple myeloma: improved patient outcomes with combo therapy

Multiple myeloma patients treated with daratumumab combined with standard chemotherapy lived longer without disease progression, a new study finds.

Ixazomib promising for treatment-resistant multiple myeloma

Clinical results reveal the effectiveness of ixazomib plus lenalidomide and dexamethasone in treating patients with relapsed and/or refractory multiple myeloma.

Imbruvica shows better results than chemo in leukemia patients

Chronic lymphocytic leukemia patients decreased more the risk of death when treated with the cancer drug Imbruvica instead of the chemotherapy chlorambucil.

Warfarin: an acceptable treatment for cancer-associated thrombosis

Warfarin can be used for the long-term treatment of cancer-associated thrombosis, in place of standard treatment low-molecular-weight heparin, a new study suggests.

Carfilzomib increased survival rate in relapsed multiple myeloma

Relapsed multiple myeloma patients treated with carfilzomib plus dexamethasone instead of bortezomib plus dexamethasone lived twice as long without disease progression.

Is watchful waiting really included in prostate cancer management?

Scientists reveal that very few low-risk prostate cancer patients followed by watchful waiting are closely monitored as called for in current guidelines.

Best treatment option for breast implant-associated cancer

Complete surgical excision proved to be the best treatment for breast implant-associated anaplastic large-cell lymphoma patients as it led to low recurrence rates.

Depression: a survival predictor in head and neck cancer

A new study reveals that depression has a profound impact on five-year survival and recurrence in head and neck cancer patients.

Antidepressant use and breast-cancer recurrence

No link was identified between risk of recurrence and antidepressant use in breast cancer patients taking an anti-cancer drug and an antidepressant.

Breast cancer: surgery linked to positive patient results

Initial breast surgery was linked to increased and durable survival rates in women with stage IV breast cancer, a new study points out.

Managing stress help women deal with breast cancer

Learning how to manage stress early in their breast cancer treatment helped patients live longer without the disease, a randomized trial shows.

Elotuzumab (Empliciti) gets FDA approval for myeloma

The monoclonal antibody, Elotuzumab, received FDA’s approval to be used for the treatment of myeloma in combination with lenalidomide (Revlimid) and dexamethasone.

EU gets closer to the treatment of Merkel cell carcinoma

European regulators have taken a step closer to the treatment of Merkel cell carcinoma, adopting a positive opinion for Orphan Drug designation for avelumab.

Immuno-oncology treatment for multiple myeloma gets US approval

The FDA approved the immuno-oncology treatment, Empliciti, for the treatment of patients with multiple myeloma.

Soccer counters prostate cancer treatment-related side effects

Prostate cancer patients playing soccer a few times a week improved muscular strength and bone density, tackling treatment-related side effects.

Login to your account

Did you forget your password?